Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism - A meta-analysis

被引:599
作者
Linkins, LA
Choi, PT
Douketis, JD
机构
[1] McMaster Univ, Hamilton, ON, Canada
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
关键词
D O I
10.7326/0003-4819-139-11-200312020-00007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Clinicians should consider the clinical impact of anticoagulant-related bleeding when deciding on the duration of anticoagulant therapy in patients with venous thromboembolism. Purpose: To provide reliable estimates of the clinical impact of anticoagulant-related bleeding, defined as the case-fatality rate of major bleeding and the risk for intracranial bleeding. Data Sources: MEDLINE (January 1989 to May 2003), Cochrane Controlled Trial Registry, thromboembolism experts, and reference lists; English-language literature only. Study Selection: Randomized, controlled trials and prospective cohort studies that investigated patients with venous thromboembolism who received oral anticoagulant therapy (target international normalized ratio, 2.0 to 3.0) for at least 3 months and that reported major bleeding and death as primary study outcomes. Data Extraction: Two reviewers independently extracted data on the number of anticoagulant-related major and intracranial bleeding episodes and on whether these events were fatal or nonfatal. Data Synthesis: The authors analyzed 33 studies involving 4374 patient-years of oral anticoagulant therapy. For all patients, the case-fatality rate of major bleeding was 13.4% (95% CI, 9.4% to 17.4%) and the rate of intracranial bleeding was 1.15 per 100 patient-years (CI, 1.14 to 1.16 per 100 patient-years). For patients who received anticoagulant therapy for more than 3 months, the case-fatality rate of major bleeding was 9.1% (CI, 2.5% to 21.7%), and the rate of intracranial bleeding was 0.65 per 100 patient-years (CI, 0.63 to 0.68 per 100 patient-years) after the initial 3 months of anticoagulation. Conclusion: The clinical impact of anticoagulant-related major bleeding in patients with venous thromboembolism is considerable, and clinicians should take this into account when deciding whether to continue long-term oral anticoagulant therapy in an individual patient.
引用
收藏
页码:893 / 900
页数:8
相关论文
共 68 条
  • [1] Extended oral anticoagulant therapy after a first episode of pulmonary embolism
    Agnelli, G
    Prandoni, P
    Becattini, C
    Silingardi, M
    Taliani, MR
    Miccio, M
    Imberti, D
    Poggio, R
    Ageno, W
    Pogliani, E
    Porro, F
    Zonzin, P
    [J]. ANNALS OF INTERNAL MEDICINE, 2003, 139 (01) : 19 - 25
  • [2] Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis.
    Agnelli, G
    Prandoni, P
    Santamaria, MG
    Bagatella, P
    Iorio, A
    Bazzan, M
    Moia, M
    Guazzaloca, G
    Bertoldi, A
    Tomasi, C
    Scannapieco, G
    Ageno, W
    Ascani, A
    Villalta, S
    Frulla, M
    Mosena, L
    Girolami, A
    Vaccarino, A
    Alatri, A
    Palareti, G
    Marchesi, M
    Ambrosio, GB
    Parisi, R
    Doria, S
    Steidl, L
    Ambrosini, F
    Silingardi, M
    Ghirarduzzi, A
    Iori, I
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) : 165 - 169
  • [3] Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis
    Anand, SS
    Yusuf, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2058 - 2067
  • [4] A POPULATION-BASED PERSPECTIVE OF THE HOSPITAL INCIDENCE AND CASE-FATALITY RATES OF DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM - THE WORCESTER DVT STUDY
    ANDERSON, FA
    WHEELER, HB
    GOLDBERG, RJ
    HOSMER, DW
    PATWARDHAN, NA
    JOVANOVIC, B
    FORCIER, A
    DALEN, JE
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (05) : 933 - 938
  • [5] The thrombophilias: Well-defined risk factors with uncertain therapeutic implications
    Bauer, KA
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 135 (05) : 367 - 373
  • [6] Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin -: The vascular Midi-Pyrenees study
    Boccalon, H
    Elias, A
    Chalé, JJ
    Cadène, A
    Gabriel, S
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (12) : 1769 - 1773
  • [7] Bounameaux H, 1997, THROMB HAEMOSTASIS, V78, P997
  • [8] ACENOCOUMAROL AND HEPARIN COMPARED WITH ACENOCOUMAROL ALONE IN THE INITIAL TREATMENT OF PROXIMAL-VEIN THROMBOSIS
    BRANDJES, DPM
    HEIJBOER, H
    BULLER, HR
    DERIJK, M
    JAGT, H
    TENCATE, JW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (21) : 1485 - 1489
  • [9] Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin, HK
    Hach-Wunderle, V
    Nakov, R
    Kakkar, VV
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (09) : 626 - 631
  • [10] Büller HR, 2000, CIRCULATION, V102, P2726